PNP
Purine nucleoside phosphorylase
Protein Summary
The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. This gene encodes an enzyme which reversibly catalyzes the phosphorolysis of purine nucleosides. The enzyme is trimeric, containing three identical subunits. Mutations which result in nucleoside phosphorylase deficiency result in defective T-cell (cell-mediated) immunity but can also affect B-cell immunity and antibody responses. Neurologic disorders may also be apparent in patients with immune defects. A known polymorphism at aa position 51 that does not affect enzyme activity has been described. A pseudogene has been identified on chromosome 2. [provided by RefSeq, Jul 2008]
- ENST00000361505
- ENSP00000354532
- ENSG00000198805
- NP
- NP
- PUNP
- PRO1837
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
disease perturbation | 1 | ||
kinase perturbation | 0.99 | ||
transcription factor perturbation | 0.96 | ||
biological process | 0.95 | ||
virus perturbation | 0.95 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 507.58 (req: < 5)
Gene RIFs: 35 (req: <= 3)
Antibodies: 290 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 507.58 (req: >= 5)
Gene RIFs: 35 (req: > 3)
Antibodies: 290 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 18
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 199
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1